Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lenses, Intraocular | 12 | 2023 | 141 | 5.650 |
Why?
|
Corneal Diseases | 24 | 2023 | 535 | 4.870 |
Why?
|
Lens Implantation, Intraocular | 15 | 2024 | 192 | 4.330 |
Why?
|
Cornea | 31 | 2023 | 1316 | 3.870 |
Why?
|
Keratoconus | 11 | 2023 | 112 | 3.690 |
Why?
|
Corneal Transplantation | 13 | 2022 | 315 | 3.640 |
Why?
|
Fuchs' Endothelial Dystrophy | 7 | 2024 | 103 | 3.610 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 11 | 2024 | 110 | 3.470 |
Why?
|
Descemet Membrane | 7 | 2021 | 70 | 3.210 |
Why?
|
Cataract | 13 | 2024 | 837 | 3.000 |
Why?
|
Phacoemulsification | 9 | 2020 | 151 | 2.440 |
Why?
|
Visual Acuity | 34 | 2024 | 2708 | 2.400 |
Why?
|
Keratomileusis, Laser In Situ | 10 | 2014 | 81 | 2.380 |
Why?
|
Sclera | 6 | 2021 | 189 | 2.150 |
Why?
|
Corneal Edema | 5 | 2024 | 45 | 2.040 |
Why?
|
Astigmatism | 8 | 2019 | 69 | 1.880 |
Why?
|
Refraction, Ocular | 5 | 2019 | 188 | 1.870 |
Why?
|
Cataract Extraction | 10 | 2023 | 464 | 1.810 |
Why?
|
Mucopolysaccharidosis I | 4 | 2022 | 53 | 1.550 |
Why?
|
Corneal Topography | 10 | 2023 | 69 | 1.530 |
Why?
|
Erythema | 2 | 2023 | 262 | 1.520 |
Why?
|
Iris | 6 | 2023 | 232 | 1.460 |
Why?
|
Corneal Ulcer | 7 | 2023 | 125 | 1.450 |
Why?
|
Trigeminal Nerve Diseases | 2 | 2021 | 47 | 1.420 |
Why?
|
Prostheses and Implants | 9 | 2022 | 1273 | 1.390 |
Why?
|
Refractive Surgical Procedures | 3 | 2019 | 21 | 1.320 |
Why?
|
Nerve Transfer | 2 | 2021 | 138 | 1.300 |
Why?
|
Eye | 2 | 2023 | 710 | 1.270 |
Why?
|
Intraoperative Complications | 4 | 2024 | 1162 | 1.250 |
Why?
|
Artificial Organs | 4 | 2016 | 149 | 1.220 |
Why?
|
Lasers, Excimer | 6 | 2015 | 68 | 1.160 |
Why?
|
Eye Diseases | 3 | 2023 | 659 | 1.130 |
Why?
|
Anterior Eye Segment | 4 | 2012 | 144 | 1.100 |
Why?
|
Corneal Opacity | 4 | 2015 | 52 | 1.060 |
Why?
|
Keratitis | 6 | 2012 | 239 | 1.020 |
Why?
|
Myopia | 9 | 2010 | 254 | 1.020 |
Why?
|
Hyperopia | 3 | 2019 | 41 | 1.010 |
Why?
|
Eye Infections, Fungal | 5 | 2014 | 99 | 1.000 |
Why?
|
Lens Subluxation | 2 | 2016 | 23 | 0.950 |
Why?
|
Ophthalmology | 5 | 2023 | 561 | 0.900 |
Why?
|
Coloboma | 2 | 2023 | 60 | 0.890 |
Why?
|
Eye Infections, Bacterial | 6 | 2014 | 239 | 0.890 |
Why?
|
Presbyopia | 2 | 2016 | 10 | 0.890 |
Why?
|
Corneal Stroma | 6 | 2020 | 166 | 0.870 |
Why?
|
Pseudophakia | 3 | 2021 | 60 | 0.850 |
Why?
|
Corneal Wavefront Aberration | 2 | 2013 | 7 | 0.830 |
Why?
|
Aberrometry | 2 | 2013 | 8 | 0.830 |
Why?
|
Iris Diseases | 1 | 2023 | 36 | 0.820 |
Why?
|
Smallpox | 1 | 2023 | 43 | 0.820 |
Why?
|
Mucopolysaccharidoses | 2 | 2022 | 27 | 0.810 |
Why?
|
Vaccinia | 1 | 2023 | 71 | 0.800 |
Why?
|
Postoperative Complications | 15 | 2021 | 15747 | 0.800 |
Why?
|
Suture Techniques | 6 | 2021 | 773 | 0.770 |
Why?
|
Vision Disorders | 6 | 2016 | 1087 | 0.750 |
Why?
|
Eye Injuries | 5 | 2023 | 228 | 0.730 |
Why?
|
beta-Alanine | 1 | 2021 | 83 | 0.720 |
Why?
|
Contact Lenses | 2 | 2012 | 137 | 0.690 |
Why?
|
Photorefractive Keratectomy | 3 | 2008 | 34 | 0.690 |
Why?
|
Anterior Chamber | 5 | 2024 | 194 | 0.680 |
Why?
|
Endothelium, Corneal | 4 | 2020 | 212 | 0.670 |
Why?
|
Benzoates | 1 | 2021 | 213 | 0.660 |
Why?
|
Sutures | 2 | 2021 | 284 | 0.650 |
Why?
|
Eye Abnormalities | 2 | 2013 | 243 | 0.630 |
Why?
|
Prosthesis Implantation | 6 | 2016 | 595 | 0.630 |
Why?
|
Nausea | 1 | 2021 | 680 | 0.600 |
Why?
|
Aphakia, Postcataract | 1 | 2017 | 51 | 0.560 |
Why?
|
Uveal Neoplasms | 2 | 2017 | 343 | 0.550 |
Why?
|
Tomography, Optical Coherence | 5 | 2024 | 2932 | 0.540 |
Why?
|
Retinal Dystrophies | 1 | 2017 | 65 | 0.540 |
Why?
|
Ectopia Lentis | 1 | 2016 | 20 | 0.540 |
Why?
|
Prosthesis-Related Infections | 2 | 2012 | 496 | 0.530 |
Why?
|
Keratoplasty, Penetrating | 7 | 2022 | 143 | 0.530 |
Why?
|
Fluoroquinolones | 3 | 2011 | 307 | 0.510 |
Why?
|
Lens, Crystalline | 4 | 2016 | 387 | 0.490 |
Why?
|
Uveitis, Anterior | 2 | 2023 | 103 | 0.490 |
Why?
|
Lens Capsule, Crystalline | 2 | 2013 | 38 | 0.490 |
Why?
|
Eyeglasses | 1 | 2016 | 138 | 0.490 |
Why?
|
Ophthalmic Solutions | 5 | 2024 | 312 | 0.480 |
Why?
|
Iridectomy | 1 | 2015 | 48 | 0.480 |
Why?
|
Uveitis | 2 | 2023 | 398 | 0.460 |
Why?
|
Copper | 1 | 2017 | 367 | 0.460 |
Why?
|
Photophobia | 1 | 2015 | 87 | 0.460 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2019 | 698 | 0.450 |
Why?
|
Elastic Modulus | 6 | 2019 | 208 | 0.450 |
Why?
|
Humans | 117 | 2024 | 765968 | 0.440 |
Why?
|
Blindness | 2 | 2015 | 586 | 0.440 |
Why?
|
Headache | 1 | 2021 | 1259 | 0.420 |
Why?
|
Posterior Eye Segment | 1 | 2013 | 18 | 0.410 |
Why?
|
Endophthalmitis | 2 | 2014 | 263 | 0.410 |
Why?
|
Corneal Surgery, Laser | 1 | 2012 | 9 | 0.410 |
Why?
|
Optics and Photonics | 1 | 2014 | 305 | 0.410 |
Why?
|
Cosmetic Techniques | 2 | 2012 | 149 | 0.410 |
Why?
|
Coloring Agents | 1 | 2015 | 564 | 0.400 |
Why?
|
Alcaligenes | 1 | 2011 | 1 | 0.390 |
Why?
|
Glaucoma | 3 | 2022 | 1194 | 0.380 |
Why?
|
Conjunctiva | 4 | 2011 | 477 | 0.370 |
Why?
|
Accommodation, Ocular | 2 | 2016 | 47 | 0.360 |
Why?
|
Lasers, Solid-State | 2 | 2010 | 183 | 0.360 |
Why?
|
Graft Survival | 3 | 2020 | 3890 | 0.350 |
Why?
|
Aspergillosis | 1 | 2012 | 242 | 0.350 |
Why?
|
Physical Examination | 1 | 2016 | 1266 | 0.340 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2011 | 239 | 0.340 |
Why?
|
Keratotomy, Radial | 1 | 2009 | 3 | 0.340 |
Why?
|
Anesthesia | 1 | 2021 | 1590 | 0.340 |
Why?
|
Glaucoma, Angle-Closure | 1 | 2012 | 192 | 0.340 |
Why?
|
Dry Eye Syndromes | 1 | 2014 | 384 | 0.330 |
Why?
|
Ocular Hypertension | 2 | 2008 | 211 | 0.330 |
Why?
|
Prosthesis Fitting | 1 | 2010 | 74 | 0.330 |
Why?
|
Acanthamoeba Keratitis | 2 | 2007 | 14 | 0.320 |
Why?
|
Cell Count | 3 | 2020 | 1823 | 0.310 |
Why?
|
Sensation Disorders | 1 | 2010 | 160 | 0.310 |
Why?
|
Keratitis, Herpetic | 1 | 2009 | 76 | 0.310 |
Why?
|
Ketorolac Tromethamine | 2 | 2006 | 21 | 0.300 |
Why?
|
Mycobacterium chelonae | 1 | 2007 | 12 | 0.290 |
Why?
|
Epithelium, Corneal | 3 | 2023 | 246 | 0.280 |
Why?
|
Virus Activation | 1 | 2009 | 323 | 0.280 |
Why?
|
Scleritis | 1 | 2007 | 96 | 0.270 |
Why?
|
Retrospective Studies | 23 | 2023 | 81514 | 0.270 |
Why?
|
Iatrogenic Disease | 1 | 2009 | 553 | 0.260 |
Why?
|
Wounds, Nonpenetrating | 1 | 2013 | 807 | 0.260 |
Why?
|
Prednisolone | 5 | 2009 | 324 | 0.260 |
Why?
|
Developing Countries | 3 | 2015 | 2911 | 0.260 |
Why?
|
Monkeypox virus | 2 | 2023 | 43 | 0.260 |
Why?
|
Drug Resistance, Bacterial | 3 | 2008 | 1069 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5696 | 0.240 |
Why?
|
Middle Aged | 33 | 2024 | 223009 | 0.230 |
Why?
|
Reoperation | 4 | 2020 | 4294 | 0.230 |
Why?
|
Optic Nerve Diseases | 1 | 2008 | 343 | 0.220 |
Why?
|
Male | 42 | 2024 | 363698 | 0.220 |
Why?
|
Edetic Acid | 1 | 2024 | 274 | 0.220 |
Why?
|
Herpesvirus 1, Human | 1 | 2009 | 743 | 0.210 |
Why?
|
Aqueous Humor | 1 | 2024 | 152 | 0.210 |
Why?
|
Eye Infections | 1 | 2004 | 63 | 0.210 |
Why?
|
Capsulorhexis | 1 | 2023 | 12 | 0.210 |
Why?
|
Mass Screening | 1 | 2019 | 5446 | 0.210 |
Why?
|
Postoperative Care | 1 | 2010 | 1470 | 0.210 |
Why?
|
Contrast Sensitivity | 1 | 2024 | 252 | 0.200 |
Why?
|
Abnormalities, Multiple | 1 | 2010 | 1424 | 0.200 |
Why?
|
Female | 42 | 2024 | 396112 | 0.200 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2268 | 0.200 |
Why?
|
Scleral Diseases | 2 | 2002 | 22 | 0.200 |
Why?
|
Eye Burns | 1 | 2002 | 64 | 0.200 |
Why?
|
Eye Neoplasms | 3 | 2010 | 304 | 0.190 |
Why?
|
Treatment Outcome | 16 | 2024 | 65188 | 0.190 |
Why?
|
Device Removal | 3 | 2012 | 646 | 0.190 |
Why?
|
Prosthesis Design | 4 | 2021 | 2105 | 0.190 |
Why?
|
Polypropylenes | 1 | 2021 | 63 | 0.180 |
Why?
|
Aged | 19 | 2024 | 171117 | 0.180 |
Why?
|
Glaucoma Drainage Implants | 1 | 2022 | 107 | 0.180 |
Why?
|
Microscopy, Confocal | 4 | 2016 | 1966 | 0.180 |
Why?
|
Tonometry, Ocular | 1 | 2021 | 238 | 0.170 |
Why?
|
Keratoconjunctivitis | 2 | 1998 | 41 | 0.170 |
Why?
|
Decision Support Techniques | 1 | 2010 | 2003 | 0.170 |
Why?
|
Lacerations | 1 | 2002 | 150 | 0.170 |
Why?
|
Drug Therapy, Combination | 5 | 2012 | 6309 | 0.170 |
Why?
|
rho-Associated Kinases | 1 | 2021 | 291 | 0.160 |
Why?
|
Rupture, Spontaneous | 2 | 2013 | 359 | 0.160 |
Why?
|
Intraocular Pressure | 3 | 2022 | 1304 | 0.160 |
Why?
|
Adult | 27 | 2023 | 223044 | 0.150 |
Why?
|
Learning Curve | 1 | 2020 | 232 | 0.150 |
Why?
|
Ciliary Body | 2 | 1997 | 168 | 0.150 |
Why?
|
Capsule Opacification | 1 | 2017 | 3 | 0.150 |
Why?
|
Surgical Wound Infection | 1 | 2007 | 1543 | 0.150 |
Why?
|
Models, Theoretical | 1 | 2010 | 3564 | 0.140 |
Why?
|
Adenovirus Infections, Human | 1 | 1998 | 76 | 0.140 |
Why?
|
Anesthesia, Local | 1 | 2000 | 276 | 0.140 |
Why?
|
Anti-Bacterial Agents | 5 | 2011 | 7478 | 0.140 |
Why?
|
Eye Infections, Viral | 1 | 1998 | 61 | 0.140 |
Why?
|
Spectrum Analysis | 1 | 2019 | 443 | 0.140 |
Why?
|
Health Care Costs | 1 | 2010 | 3242 | 0.140 |
Why?
|
Acute Disease | 2 | 2021 | 7232 | 0.140 |
Why?
|
Burns, Chemical | 1 | 2018 | 123 | 0.140 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 252 | 0.130 |
Why?
|
Choroid Neoplasms | 1 | 1998 | 175 | 0.130 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 1996 | 48 | 0.130 |
Why?
|
Drug Implants | 1 | 2016 | 230 | 0.130 |
Why?
|
Hot Temperature | 1 | 2002 | 1433 | 0.130 |
Why?
|
Elasticity | 2 | 2015 | 652 | 0.120 |
Why?
|
Glare | 1 | 2015 | 6 | 0.120 |
Why?
|
Glaucoma, Open-Angle | 2 | 2021 | 742 | 0.120 |
Why?
|
Cysts | 1 | 2020 | 684 | 0.120 |
Why?
|
Patient Satisfaction | 2 | 2018 | 3475 | 0.120 |
Why?
|
Wounds, Penetrating | 1 | 1997 | 317 | 0.120 |
Why?
|
Axial Length, Eye | 1 | 2014 | 36 | 0.120 |
Why?
|
Homosexuality, Male | 1 | 2023 | 1342 | 0.120 |
Why?
|
Pigmentation | 1 | 2015 | 143 | 0.120 |
Why?
|
Melanoma, Experimental | 1 | 1998 | 558 | 0.110 |
Why?
|
Antibiotic Prophylaxis | 2 | 2014 | 644 | 0.110 |
Why?
|
Intravitreal Injections | 1 | 2016 | 401 | 0.110 |
Why?
|
Retinal Diseases | 2 | 2018 | 709 | 0.110 |
Why?
|
Air | 2 | 2013 | 181 | 0.110 |
Why?
|
Follow-Up Studies | 8 | 2022 | 39193 | 0.110 |
Why?
|
Bioartificial Organs | 1 | 2014 | 46 | 0.110 |
Why?
|
Collagen | 2 | 2013 | 2618 | 0.110 |
Why?
|
Vitrectomy | 1 | 2016 | 389 | 0.110 |
Why?
|
Cogan Syndrome | 1 | 2013 | 10 | 0.110 |
Why?
|
Crystallins | 1 | 1993 | 75 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1759 | 0.110 |
Why?
|
Endotamponade | 1 | 2013 | 37 | 0.100 |
Why?
|
Apraxias | 1 | 2013 | 58 | 0.100 |
Why?
|
Blepharitis | 2 | 2005 | 37 | 0.100 |
Why?
|
Silicone Elastomers | 1 | 2012 | 78 | 0.100 |
Why?
|
Trichosporon | 1 | 2012 | 9 | 0.100 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2012 | 24 | 0.100 |
Why?
|
Lacrimal Apparatus | 1 | 2014 | 224 | 0.100 |
Why?
|
Lupus Erythematosus, Discoid | 2 | 2005 | 61 | 0.100 |
Why?
|
Aza Compounds | 1 | 2011 | 34 | 0.100 |
Why?
|
Standard of Care | 1 | 2016 | 567 | 0.090 |
Why?
|
Intraoperative Period | 1 | 2012 | 508 | 0.090 |
Why?
|
Wound Healing | 1 | 2002 | 2792 | 0.090 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 2007 | 354 | 0.090 |
Why?
|
Conjunctivitis | 2 | 2005 | 153 | 0.090 |
Why?
|
Refractive Errors | 1 | 2013 | 148 | 0.090 |
Why?
|
Cross-Linking Reagents | 2 | 2013 | 687 | 0.090 |
Why?
|
Biometry | 1 | 2014 | 571 | 0.090 |
Why?
|
Tissue Donors | 1 | 2021 | 2395 | 0.090 |
Why?
|
Microbial Sensitivity Tests | 3 | 2008 | 1971 | 0.090 |
Why?
|
Aspergillus fumigatus | 1 | 2012 | 158 | 0.090 |
Why?
|
Immunoenzyme Techniques | 2 | 2010 | 1701 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2016 | 777 | 0.090 |
Why?
|
Pilot Projects | 2 | 2021 | 8733 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2016 | 790 | 0.090 |
Why?
|
Sudan | 1 | 2010 | 86 | 0.090 |
Why?
|
Polymethyl Methacrylate | 1 | 2011 | 126 | 0.090 |
Why?
|
Stromal Cells | 1 | 2016 | 1329 | 0.090 |
Why?
|
Program Development | 1 | 2016 | 1295 | 0.090 |
Why?
|
Retinoblastoma | 1 | 1993 | 316 | 0.090 |
Why?
|
Microscopy | 2 | 2020 | 901 | 0.090 |
Why?
|
Glucocorticoids | 3 | 2009 | 2132 | 0.090 |
Why?
|
Neurilemmoma | 1 | 1995 | 522 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2002 | 3681 | 0.080 |
Why?
|
Goldenhar Syndrome | 1 | 2010 | 40 | 0.080 |
Why?
|
Curriculum | 1 | 2023 | 3782 | 0.080 |
Why?
|
Antifungal Agents | 2 | 2012 | 769 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 3 | 2018 | 1808 | 0.080 |
Why?
|
Vimentin | 1 | 2010 | 258 | 0.080 |
Why?
|
Retina | 2 | 2018 | 2657 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2226 | 0.080 |
Why?
|
Visually Impaired Persons | 1 | 2010 | 79 | 0.080 |
Why?
|
Elasticity Imaging Techniques | 1 | 2014 | 398 | 0.080 |
Why?
|
Dermoid Cyst | 1 | 2010 | 91 | 0.080 |
Why?
|
Sickness Impact Profile | 1 | 2010 | 297 | 0.080 |
Why?
|
Aged, 80 and over | 6 | 2024 | 59489 | 0.080 |
Why?
|
Finland | 1 | 2010 | 608 | 0.080 |
Why?
|
Mycoses | 2 | 2007 | 389 | 0.080 |
Why?
|
Keratins | 1 | 2010 | 498 | 0.080 |
Why?
|
Acyclovir | 1 | 2009 | 267 | 0.070 |
Why?
|
Surgical Flaps | 2 | 2007 | 1677 | 0.070 |
Why?
|
Titanium | 1 | 2011 | 490 | 0.070 |
Why?
|
Ethiopia | 1 | 2010 | 485 | 0.070 |
Why?
|
Graft Rejection | 1 | 2021 | 4499 | 0.070 |
Why?
|
Benzamidines | 1 | 2007 | 20 | 0.070 |
Why?
|
Chloramphenicol | 1 | 2007 | 67 | 0.070 |
Why?
|
Biguanides | 1 | 2007 | 20 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2020 | 2418 | 0.070 |
Why?
|
Alternaria | 1 | 2007 | 41 | 0.070 |
Why?
|
Postoperative Period | 1 | 2012 | 1816 | 0.070 |
Why?
|
Eyelids | 1 | 2010 | 279 | 0.070 |
Why?
|
Aniridia | 1 | 2007 | 36 | 0.070 |
Why?
|
Corneal Neovascularization | 1 | 2009 | 184 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4255 | 0.070 |
Why?
|
Clarithromycin | 1 | 2007 | 87 | 0.070 |
Why?
|
Papilledema | 1 | 2008 | 130 | 0.070 |
Why?
|
Models, Economic | 1 | 2010 | 716 | 0.060 |
Why?
|
Photosensitizing Agents | 1 | 2010 | 625 | 0.060 |
Why?
|
Quinolines | 1 | 2011 | 769 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2535 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2006 | 208 | 0.060 |
Why?
|
India | 1 | 2012 | 2334 | 0.060 |
Why?
|
Ultraviolet Rays | 1 | 2010 | 1102 | 0.060 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2120 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 1668 | 0.060 |
Why?
|
Prospective Studies | 4 | 2021 | 54802 | 0.060 |
Why?
|
Photochemotherapy | 1 | 2010 | 826 | 0.060 |
Why?
|
Syndrome | 1 | 2010 | 3271 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1737 | 0.050 |
Why?
|
Electrocoagulation | 1 | 2004 | 157 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2010 | 2424 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2013 | 18293 | 0.050 |
Why?
|
Chelating Agents | 1 | 2024 | 380 | 0.050 |
Why?
|
Isoindoles | 1 | 2022 | 35 | 0.050 |
Why?
|
Health Services Research | 1 | 2010 | 1808 | 0.050 |
Why?
|
Trifluridine | 1 | 2022 | 27 | 0.050 |
Why?
|
Antiviral Agents | 2 | 2009 | 3050 | 0.050 |
Why?
|
Adolescent | 6 | 2016 | 88835 | 0.050 |
Why?
|
Down Syndrome | 1 | 2010 | 915 | 0.050 |
Why?
|
Activities of Daily Living | 1 | 2010 | 2415 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5337 | 0.040 |
Why?
|
Retrobulbar Hemorrhage | 1 | 2000 | 10 | 0.040 |
Why?
|
Eye Injuries, Penetrating | 1 | 2002 | 121 | 0.040 |
Why?
|
Child, Preschool | 5 | 2010 | 42500 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 986 | 0.040 |
Why?
|
Aging | 2 | 2016 | 8731 | 0.040 |
Why?
|
Disease Progression | 2 | 2014 | 13632 | 0.040 |
Why?
|
Stress, Mechanical | 2 | 2016 | 1668 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2009 | 2056 | 0.040 |
Why?
|
Fundus Oculi | 2 | 1998 | 559 | 0.040 |
Why?
|
Optic Nerve Injuries | 1 | 2000 | 150 | 0.040 |
Why?
|
Prognosis | 3 | 2007 | 29922 | 0.040 |
Why?
|
Ultrasonography | 2 | 2006 | 5993 | 0.040 |
Why?
|
Sclerostomy | 1 | 1998 | 16 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2007 | 8529 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 1998 | 6113 | 0.040 |
Why?
|
Tromethamine | 1 | 1997 | 30 | 0.040 |
Why?
|
Tolmetin | 1 | 1997 | 24 | 0.040 |
Why?
|
Child | 6 | 2020 | 80564 | 0.040 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2018 | 93 | 0.040 |
Why?
|
Occlusive Dressings | 1 | 1997 | 52 | 0.040 |
Why?
|
Benzamides | 1 | 2023 | 1377 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5526 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2024 | 12437 | 0.030 |
Why?
|
Injections | 1 | 2000 | 840 | 0.030 |
Why?
|
Laser Therapy | 1 | 2004 | 1108 | 0.030 |
Why?
|
Amyloid beta-Peptides | 1 | 2010 | 3896 | 0.030 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 1998 | 235 | 0.030 |
Why?
|
Risk Factors | 3 | 2022 | 74840 | 0.030 |
Why?
|
Orbit | 1 | 2000 | 456 | 0.030 |
Why?
|
History, 20th Century | 1 | 2004 | 2761 | 0.030 |
Why?
|
ROC Curve | 1 | 2023 | 3620 | 0.030 |
Why?
|
Oculomotor Muscles | 1 | 2000 | 404 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 3 | 2014 | 4034 | 0.030 |
Why?
|
Incidence | 4 | 2022 | 21480 | 0.030 |
Why?
|
Phlebitis | 1 | 1995 | 34 | 0.030 |
Why?
|
Retinal Vein | 1 | 1995 | 46 | 0.030 |
Why?
|
Central Nervous System Diseases | 1 | 2000 | 518 | 0.030 |
Why?
|
Gonioscopy | 1 | 1995 | 157 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 286 | 0.030 |
Why?
|
Fluorescein Angiography | 2 | 1998 | 1085 | 0.030 |
Why?
|
United States | 4 | 2022 | 72903 | 0.030 |
Why?
|
Rabbits | 2 | 1998 | 4734 | 0.030 |
Why?
|
Pressure | 1 | 1997 | 1168 | 0.030 |
Why?
|
Paraneoplastic Syndromes | 1 | 1995 | 156 | 0.030 |
Why?
|
Administration, Topical | 2 | 2009 | 704 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2006 | 10729 | 0.030 |
Why?
|
Infant | 4 | 2010 | 36386 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13648 | 0.030 |
Why?
|
Anesthetics, Local | 1 | 2000 | 1015 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9249 | 0.020 |
Why?
|
Pigmentation Disorders | 1 | 1992 | 106 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 1995 | 2548 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15880 | 0.020 |
Why?
|
Macaca | 1 | 1993 | 413 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13451 | 0.020 |
Why?
|
Blotting, Northern | 1 | 1993 | 1546 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2018 | 959 | 0.020 |
Why?
|
Animals | 8 | 2016 | 168764 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 752 | 0.020 |
Why?
|
Fibrosis | 1 | 1998 | 2070 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1641 | 0.020 |
Why?
|
Riboflavin | 1 | 2010 | 108 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 1998 | 3602 | 0.020 |
Why?
|
China | 1 | 2015 | 2385 | 0.020 |
Why?
|
Protein Structure, Quaternary | 1 | 2010 | 423 | 0.020 |
Why?
|
Epinephrine | 1 | 1992 | 783 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2010 | 8730 | 0.020 |
Why?
|
Steroids | 1 | 1994 | 933 | 0.020 |
Why?
|
Scattering, Radiation | 1 | 2010 | 482 | 0.020 |
Why?
|
Hydroxychloroquine | 2 | 2005 | 431 | 0.020 |
Why?
|
Polymyxin B | 1 | 2007 | 43 | 0.020 |
Why?
|
Trimethoprim | 1 | 2007 | 79 | 0.020 |
Why?
|
Itraconazole | 1 | 2007 | 42 | 0.020 |
Why?
|
Ofloxacin | 1 | 2007 | 66 | 0.020 |
Why?
|
Cefazolin | 1 | 2008 | 94 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3608 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2005 | 7425 | 0.020 |
Why?
|
Biopsy | 2 | 1999 | 6763 | 0.020 |
Why?
|
Amphotericin B | 1 | 2007 | 140 | 0.020 |
Why?
|
Gentamicins | 1 | 2008 | 244 | 0.020 |
Why?
|
Eye Proteins | 1 | 2010 | 628 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2018 | 4348 | 0.020 |
Why?
|
Cattle | 1 | 2012 | 3801 | 0.020 |
Why?
|
Ciprofloxacin | 1 | 2008 | 314 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22223 | 0.020 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2008 | 339 | 0.020 |
Why?
|
Debridement | 1 | 2007 | 495 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15842 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20124 | 0.010 |
Why?
|
Radiography | 1 | 1995 | 6919 | 0.010 |
Why?
|
Light | 1 | 2010 | 1365 | 0.010 |
Why?
|
Brain | 1 | 2010 | 27171 | 0.010 |
Why?
|
Swine | 1 | 2013 | 5988 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7421 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3946 | 0.010 |
Why?
|
Time Factors | 4 | 2011 | 40065 | 0.010 |
Why?
|
Pain | 1 | 1997 | 5077 | 0.010 |
Why?
|
Young Adult | 3 | 2016 | 59889 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12056 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2010 | 4860 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 1989 | 2729 | 0.010 |
Why?
|
Drug Combinations | 1 | 2007 | 2077 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11206 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13266 | 0.010 |
Why?
|
Electroretinography | 2 | 1995 | 526 | 0.010 |
Why?
|
Gene Expression | 1 | 1993 | 7584 | 0.010 |
Why?
|
Rupture | 1 | 2002 | 443 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26318 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 22332 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 1997 | 36532 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2010 | 13400 | 0.010 |
Why?
|
Mice | 2 | 1998 | 81819 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3513 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1993 | 12768 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16721 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2010 | 17594 | 0.010 |
Why?
|
Chronic Disease | 2 | 2005 | 9347 | 0.010 |
Why?
|
Hypertrophy | 1 | 1999 | 559 | 0.010 |
Why?
|
Melanoma | 1 | 1995 | 5719 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1995 | 5849 | 0.010 |
Why?
|
Radioisotopes | 1 | 1997 | 495 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2005 | 1365 | 0.010 |
Why?
|
Night Blindness | 1 | 1995 | 58 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2005 | 12976 | 0.010 |
Why?
|
Forecasting | 1 | 2004 | 2936 | 0.010 |
Why?
|
Retinal Rod Photoreceptor Cells | 1 | 1995 | 205 | 0.010 |
Why?
|
Uveal Diseases | 1 | 1992 | 45 | 0.010 |
Why?
|
Prolapse | 1 | 1992 | 63 | 0.010 |
Why?
|
Gadolinium | 1 | 1997 | 965 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 8041 | 0.000 |
Why?
|
Image Enhancement | 1 | 1997 | 2858 | 0.000 |
Why?
|
Optic Nerve | 1 | 1989 | 567 | 0.000 |
Why?
|
Edema | 1 | 1989 | 760 | 0.000 |
Why?
|